Gaxos.ai (NASDAQ:GXAI – Get Free Report) and Exagen (NASDAQ:XGN – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.
Institutional & Insider Ownership
42.6% of Gaxos.ai shares are owned by institutional investors. Comparatively, 75.2% of Exagen shares are owned by institutional investors. 3.2% of Gaxos.ai shares are owned by company insiders. Comparatively, 10.4% of Exagen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Gaxos.ai has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Exagen has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Gaxos.ai | -64.81% | -38.79% | -36.99% |
| Exagen | -26.61% | -104.46% | -28.93% |
Analyst Ratings
This is a summary of current recommendations and price targets for Gaxos.ai and Exagen, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gaxos.ai | 1 | 0 | 0 | 0 | 1.00 |
| Exagen | 1 | 0 | 7 | 1 | 2.89 |
Exagen has a consensus target price of $9.62, suggesting a potential upside of 14.45%. Given Exagen’s stronger consensus rating and higher probable upside, analysts plainly believe Exagen is more favorable than Gaxos.ai.
Valuation and Earnings
This table compares Gaxos.ai and Exagen”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gaxos.ai | $1.93 million | 3.34 | -$3.90 million | ($0.50) | -1.20 |
| Exagen | $66.57 million | 3.06 | -$19.95 million | ($0.81) | -10.38 |
Gaxos.ai has higher earnings, but lower revenue than Exagen. Exagen is trading at a lower price-to-earnings ratio than Gaxos.ai, indicating that it is currently the more affordable of the two stocks.
Summary
Exagen beats Gaxos.ai on 10 of the 15 factors compared between the two stocks.
About Gaxos.ai
Gaxos.ai Inc. engages in developing artificial intelligence applications for various sectors. Its portfolio includes applications in mental and physical wellbeing, coaching, and gaming. In addition, it offers Gaxos, a gaming platform develop, design, acquire, and manage conventional games and combine these games with unconventional game mechanisms. The company was formerly known as The NFT Gaming Company, Inc. and changed its name to Gaxos.ai Inc. in January 2024. Gaxos.ai Inc. was incorporated in 2021 and is based in Roseland, New Jersey.
About Exagen
Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Receive News & Ratings for Gaxos.ai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gaxos.ai and related companies with MarketBeat.com's FREE daily email newsletter.
